miRNA alterations modify kinase activation in the IGF-1 pathway and correlate with colorectal cancer stage and progression in patients

Journal of Cancer

Volumn 2, Issue 1, 2011, Pages 490-502

  Knowlton, David L ^a   Tang, Kim ^a   Henstock, Peter V ^a   Subramanian, Romesh R ^a  

^a PFIZER INC   (United States)

Author keywords

Colorectal cancer; IGF 1R pathway; miRNA; Phosphorylation events

Indexed keywords

MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ARTICLE; BIOPSY; CANCER GROWTH; CANCER STAGING; COLON CARCINOGENESIS; COLORECTAL CANCER; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN TISSUE; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 84881211610     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.2.490     Document Type: Article

References (51)

1. Liu J, Rivas F.V, Wohlschlegel J, Yates J.R, Parker R, Hannon G.J. A role for the P-body component GW182 in microRNA function. NATURE CELL BIOLOGY 2005; 7 (12): 1261 - 1266.
2. Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S.,Brown E, O'Connor M, Yau Y, Pachter J, Miglarese M, Epstein D, Iwata K, Haley J, Gibson N, Ji Q. Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-like Growth Factor Receptors. Cancer Research 2008; 68 (20): 8322 - 8332.
3. Ostrowski J, Woszczynski M, Kowalczyk P, Wocial T, Hennig E, Trzeciak L, Janik P, Bomsztyk K. Increased activity of MAP, p70S6 and p90rs kinases is associated with AP-1 activation in spontaneous liver tumors, but not in adjacent tissue in mice. British Journal of Cancer 2000; 82 (5): 1041 - 1050.
4. Reidemann J, Macaulay V. IGF1R signaling and its inhibition. Endocrine-Related Cancer 2006; 13: S33-S43.
5. Katoh M, Katoh M. Cross-talk of WNT and FGF Signaling Pathways at GSK3b to Regulate b-Catenin and SNAIL Signaling Cascades. Cancer Biology & Therapy 2006; 5 (9): 1059-1064.
6. Johnson S, Gulhati P, Rampy B, Han Y, Rychahou P, Doan H, Weiss H, Evers B. Novel Expression Patterns of PI3K/Akt/mTOR Signaling Pathway Components in Colorectal Cancer. Journal of the American College of Surgeons 2009; 210 (5): 767-776.
7. Lee S, Lee J, Soung Y, Kim S, Nam S, Park W, Kim S, Yoo N, Lee J. Colorectal tumors frequently express phosphorylated Mitogen-activated protein kinase. Acta Pathologica, Microbiologica et Immunologica Scandinavica 2004; 112: 233-238.
8. Zumkeller W. Epidemiological Approaches to Evaluating Insulin-Like Growth Factor and Cancer Risk. In: LeRoith D, Zumkeller W., Baxter R.C., Eds. Insulin-like Growth Factors. Texas: Landes Bioscience. 2003: 329-333.
9. Slattery M.L, Samowitz W, Curtin K, Ma K.N, Hoffman M, Caan B, Neuhausen S. Association among IRS1, IRS2, IGF1 and IGFBP3 genetic polymorphism and colon cancer. Cancer Epidemiol. Biomarkers Prev 2004; 13: 1206-1214.
10. Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B. The IGF-I receptor in cell growth, transformation and apoptosis. Biochimica et Biophysica Acta 1997; 1332: F105-F126.
11. Su A, Wiltshire T, Batalov S, Lapp H, Ching K, Block D, Zhang J, Soden R, Hayakawa M, Kreiman G, Cooke M, Walker J, and Hogenesch J. A gene atlas of the mouse and human protein-encoding transcriptomes. PNAS 2004; 101 (16): 6062 - 67.
12. Betel D, Koppal A, Agius P, Sander C, Leslie C. Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biology 2010; 11: R90.
13. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: targets and expression. Nucleic Acids Res. 2008; 36: D149-53.
14. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human MicroRNA targets. PLoS Biol 2005; 3 (7): e264.
15. Enright AJ, John B, Gaul U, Tuschl T, Sander C and Marks DS. MicroRNA targets in Drosophila. Genome Biology 2003; 5: R1.
16. Ryan PD, Goss PE. The emerging role of insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 2008; 13: 16-24.
17. Dearth R, Cui X, Kim H.,. Hadsell D, Lee A. Oncogenic Transformation by the Signaling Adaptor Proteins Insulin Receptor Substrate (IRS) -1 and IRS - Cell Cycle 2007; 6 (6): 705-713.
18. Miura M, Li S, and Baserga R. Effect of a Mutation at Tyrosine 950 of the Insulin-like Growth Factor I Receptor on the Growth and Transformation of Cells. CANCER RESEARCH 1995; 55: 663-667.
19. Sehat B, Andersson S, Vasilcanu R, Girnita L, Larsson O. Role of Ubiquitination in IGF-1 Receptor Signaling and Degradation. PLOS 2007; 4: e340.
20. Chang Q, Li Y. White M, Fletcher J, and Xiao S. Constitutive Activation of Insulin Receptor Substrate 1 Is a Frequent Event in Human Tumors: Therapeutic Implications. CANCER RESEARCH 2002; 62: 6035-6038.
21. Saxena N, Taliaferro-Smith L, Knight B, Merlin D. Biodirrectional Crosstalk between Leptin and Insulin-like Growth Factor - 1 Signaling Promotes Invasion and Migration of Breast Cancer Cells via Transactivation of Epidermal Growth Factor Receptor. Cancer Res 2008; 68 (23): 9712-22.
22. Scamuffa N, Siegfried G, Bontemps Y, Ma L, Basak A, Cherel G, Calvo F, Seidah N, and Khatib A. Selective inhibition of pro-protein convertases represses the metastatic potential of human colorectal tumor cells. J. Clin. Invest 2008; 118: 352-363.
23. Tremblay F, et al. Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient-and obesity-induced insulin resistance. PNAS 2007; 104 (35): 14056-14061.
24. Um S, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Fumagalli S, Allegrini P, Kozma S, Auwerx J. and Thomas G. Absence of S6K1 protects against age-and diet-induced obesity while enhancing insulin sensitivity. NATURE 2004; 431 (9): 200-205.
25. Harrington L, Findlay G, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie N, Cheng S, Shepherd P, Gout I, Downes C, and Lamb R. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol 2004; 166: 213-223.
26. Manning B, and Cantley L. Akt/PKB Signaling: Navigating Downstream. Cell 2007; 129 (7): 1261-1274.
27. Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, Brown E, O'Connor M, Yao Y, Pachter J, Miglarese M, Epstein D, Iwata K, Haley J, Gibson N, and Ji Q. Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors. Cancer Res 2008; 68 (20): 8322-32.
28. Hennessy B, Smith D, Ram P, Lu L and Mills G. Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery. Nature Reviews Drug Discovery 2005; 4: 988-1004.
29. Roy H, Olusola B, Clemens D, Karolski W, Ratashak A, Lynch H and Smyrk T. AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 2002; 23 (1): 201-205.
30. Huang X and Chen J. Obesity, the PI3K/Akt signal pathway and colon cancer. Obesity reviews 2009; 10: 610-616.
31. Gulhati P, Cai Q, Li J, Liu J, Rychahou P, Qiu S, Lee E, Silva S, Bowen K, Gao T, and Evers B. Targeted Inhibition of Mammalian Target of Rapamycin Signaling Inhibits Tumorgenesis of Colorectal Cancer. Clinical Cancer Research 2009; 15: 7207-7216.
32. Haar E, Lee S, Bandhakavi S, Griffin T and Kim D. Insulin signalling to mTOR mediated by the Akt/PKB Substrate PRAS Nature Cell Biology 2007; 9: 316 - 323.
33. Cross D, Alessi D, Cohen P, Andjelkovich M, Hemmings B. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785-789.
34. Jope R, Yuskaitis C, and Beurel E. Glycogen Synthase Kinase-3 (GSK3): Inflamation, Diseases, and Therapeutics. Neurochem Res. 2007;32 (4-5): 577-595.
35. Kang T, Wei Y. Chiang Y, Yamaguch H, Appella E, Hung M, and Piwnica-Worms H. GSK-3β Targets Cdc25A for Ubiquitin-Mediated Proteolysis and GSK-3β Inactivation Correlates with Cdc25A Overproduction in Human Cancers. Cancer Cell 2008; 13 (1): 36-47.
36. Nozawa H, Watanabe H, Nagawa H. Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer. Cancer Letters 2007; 251: 105-113.
37. Julien L, Carriere A, Moreau J, and Roux PP. mTORC1-Activated S6K1 Phosphorylates Rictor on Threonine 1135 and Regulates mTORC2 Signaling. Molecular and Cellular biology 2010; 30 (4): 908-921.
38. Ballif B, Roux P, Gerber S, MacKeigan J, Blenis J, and Gygi S. Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. PNAS 2005; 102 (3): 667-672.
39. Remacle-Bonnet MM, Garrouste FL, Hellar S, et al. Insulin-like growth factor - I protects colon cancer cells from death factor- induced apoptosis by potentiating tumor necrosis factor alpha - induced mitogen - activated protein kinase and nuclear factor kappaB signaling pathways. Cancer Research 2000; 60: 2007 - 17.
40. Lee S, Bahn J, Whitlock N, and Baek S. Activating transcription factor 2 (ATF2) controls tolfenamic acidinduced ATF3 expression via MAP kinase pathways. Oncogene 2010; 29(37): 5182-5192.
41. Ouwens D, Ruiter N, van der Zon G, Carter A, Schouten J, van der Burgt C, Kooistra K, Bos J, Maassen J, and van Dam H. Growth factors can activate ATF2 via a two-step mechanism: Phosphorylation of Thr71 through the RAS-MEK-ERK pathway and of Thr69 through RalGDS-Src-p EMBO 2002; 21(14): 3782-3793.
42. Carriere A, Ray H, Blenis J, Roux PP. The RSK factors of activating the Ras/MAPK signaling cascade. Front Biosci 2008; 1(13): 4258-75.
43. Doehn U, Hauge C, Frank SR, Jensen CJ, Duda K, Nielsen JV, Cohen MS, Johansen JV, Winther BR, Lund LR, Winther O, Taunton J, Hansen SH, Frödin M. RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promo-tile/invasive gene program and phenotype in epithelial cells. Mol Cell 2009; 35(4): 511-22.
44. Anjum R and Blenis J. The RSK family of kinases: emerging roles in cellular signaling. Nat Rev Mol. Cell Biol 2008; 9: 747-758.
45. Beezhold1 KJ, Castranova1 V, and Chen F. Microprocessor of microRNAs: regulation and potential for therapeutic intervention. Molecular Cancer 2010; 9: 134.
46. Pasquinelli AE, and Ruvkun G. Control of Developmental timing by microRNAs and their targets. Annu Rev Cell Dev Biol 2002; 18: 495-513.
47. Xiao, Rajewsky K. Micro RNA Control in the Immune System: Basic Principles. Cell 2009; 136(1): 26-36.
48. Kim J, Inoue K, Ishii J, Vanti WB, Voronov SV, Murchison E, Hannon G, Abeliovich A. A microTNA feedback circuit in midbrain dopamine neurons. Science. 2007;317(5842):1179-80.
49. Visone R, Croce CM. MiRNAs and cancer. Am J Pathol 2009; 174(4): 1131-8.
50. Kanehisa, M, Goto, S, Furumichi, M, Tanabe, M, and Hirakawa M. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res 2010; 38: D355-D360.
51. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita K.F, Itoh M, Kawashima S, Katayama T, Araki M, and Hirakawa M. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 2006; 34: D354-357.